These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34217971)

  • 21. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
    Uchida S; Kojima T; Sugino T
    Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
    Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.
    Zhao H; Langerød A; Ji Y; Nowels KW; Nesland JM; Tibshirani R; Bukholm IK; Kåresen R; Botstein D; Børresen-Dale AL; Jeffrey SS
    Mol Biol Cell; 2004 Jun; 15(6):2523-36. PubMed ID: 15034139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomere length alterations unique to invasive lobular carcinoma.
    Heaphy CM; Asch-Kendrick R; Argani P; Meeker AK; Cimino-Mathews A
    Hum Pathol; 2015 Aug; 46(8):1197-203. PubMed ID: 26092192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
    Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
    Ding Q; Chen H; Lim B; Damodaran S; Chen W; Tripathy D; Piha-Paul S; Luthra R; Meric-Bernstam F; Sahin AA
    Hum Pathol; 2019 Oct; 92():32-38. PubMed ID: 31351155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
    Prat A; Adamo B; Cheang MC; Anders CK; Carey LA; Perou CM
    Oncologist; 2013; 18(2):123-33. PubMed ID: 23404817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
    Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
    Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
    Christgen M; Kandt LD; Antonopoulos W; Bartels S; Van Bockstal MR; Bredt M; Brito MJ; Christgen H; Colpaert C; Cserni B; Cserni G; Daemmrich ME; Danebrock R; Dedeurwaerdere F; van Deurzen CH; Erber R; Fathke C; Feist H; Fiche M; Gonzalez CA; Ter Hoeve ND; Kooreman L; Krech T; Kristiansen G; Kulka J; Laenger F; Lafos M; Lehmann U; Martin-Martinez MD; Mueller S; Pelz E; Raap M; Ravarino A; Reineke-Plaass T; Schaumann N; Schelfhout AM; De Schepper M; Schlue J; Van de Vijver K; Waelput W; Wellmann A; Graeser M; Gluz O; Kuemmel S; Nitz U; Harbeck N; Desmedt C; Floris G; Derksen PW; van Diest PJ; Vincent-Salomon A; Kreipe H
    J Pathol Clin Res; 2022 Mar; 8(2):191-205. PubMed ID: 34889530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
    Sarrió D; Moreno-Bueno G; Hardisson D; Sánchez-Estévez C; Guo M; Herman JG; Gamallo C; Esteller M; Palacios J
    Int J Cancer; 2003 Aug; 106(2):208-15. PubMed ID: 12800196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.